I'm LongbridgeAI, I can summarize articles.Neogenomics (NEO.US) gained 6.3% this week to close at $18.05, while the S&P 500 added 0.49%, leaving the stock about 5.81 percentage points ahead of the benchmark. The move was back-loaded: Monday (24 Aug) opened and closed lower at $16.41, Tuesday (25 Aug) drifted up to $16.79, and Wednesday (26 Aug) pushed to $17.37 on higher volume. The decisive session was Thursday (27 Aug), when volume jumped to 5.10m shares and the stock hit a weekly high of $19.76 before settling at $18.64.
The Week
Neogenomics (NEO.US) gained 6.3% this week to close at $18.05, while the S&P 500 added 0.49%, leaving the stock about 5.81 percentage points ahead of the benchmark. The move was back-loaded: Monday (24 Aug) opened and closed lower at $16.41, Tuesday (25 Aug) drifted up to $16.79, and Wednesday (26 Aug) pushed to $17.37 on higher volume. The decisive session was Thursday (27 Aug), when volume jumped to 5.10m shares and the stock hit a weekly high of $19.76 before settling at $18.64. Friday (28 Aug) gave back a little to finish at $18.05. Full-week amplitude reached 20.78%.
Key Events
The week’s company-specific story ran on two parallel tracks. On Wednesday (26 Aug) the company filed an S-8 registration, the standard form for share-based employee compensation plans; the filing itself is routine in nature and does not carry new financial detail, but it signals ongoing equity-based incentives. The more prominent news hit Thursday evening (27 Aug), with coverage noting that NeoGenomics stock had just turned its first profit, described as creating an optimal entry point. The two items landed either side of Thursday’s volume spike, which framed the week’s narrative. Worth flagging: the company’s static EPS is still negative at -$0.84, so the ‘first profit’ claim likely refers to a narrower or more recent metric rather than full-year GAAP profitability.
Analyst Ratings
Twelve brokers cover the stock: 6 rate it buy, 2 rate it overweight, 4 rate it hold, with no underweight or sell ratings. The consensus recommendation is buy, and the consensus target sits at $19.72, roughly 9.26% above the latest close of $18.05. The target range is wide, from a low of $16.00 to a high of $35.00, which points to meaningful disagreement about the long-term path. Within the healthcare services industry group of 53 names, NeoGenomics ranks 14th on broker ratings.
The Week Ahead
The macro calendar is dense next week. Tuesday (1 Sep) brings the S&P Global manufacturing PMI final, ISM manufacturing PMI, and US JOLTS job openings on the same day; the ISM reading comes in at 55.6 prior and 55.2 expected. Wednesday (2 Sep) adds ADP private payrolls, factory orders, and EIA crude inventory data. For a rate- and growth-sensitive healthcare services name, these readings matter mostly through shifts in market-wide risk appetite rather than through any direct operational link. NeoGenomics itself has no known earnings or company-specific event on the published calendar, so the watch items are largely external.
In Short
The tension looks like this: the sell-side skew is favourable, with a buy consensus and a target above spot, but the target range spans nearly $19, which is a wide dispersion. On valuation, the stock trades at about 2.95x price-to-book while static EPS remains negative, so there is no traditional earnings anchor yet. The latest session’s flow data shows small-lot money as a net buyer while large and medium orders lean net seller, which is a cautious skew from the bigger players. The ‘first profit’ narrative and the volume spike arrived in the same week, but the persistence of that metric needs confirmation in the next set of results. What to watch: whether next week’s macro prints shake the sector’s valuation, and whether the following earnings report shows improvement in a more conventional profit measure.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.